Novartis Looks To Recent Launches To Bolster Diovan Against Generic Onslaught
This article was originally published in The Pink Sheet Daily
Executive Summary
The Swiss pharma predicts hypertension blockbuster still will earn $2 billion annually outside the U.S. after patent expirations.
You may also be interested in...
Novartis Splits Chair and CEO Positions, Names Joe Jimenez CEO
The news eclipses reports of a strong 2009, in which Novartis received 30 major regulatory approvals, and saw sales grow across major divisions
Novartis Splits Chair and CEO Positions, Names Joe Jimenez CEO
The news eclipses reports of a strong 2009, in which Novartis received 30 major regulatory approvals, and saw sales grow across major divisions
Bristol Myers-Squibb/AstraZeneca's Onglyza Officially Cleared For Europe
New DPP-4 inhibitor for diabetes passes noninferiority test against Merck's hugely popular Januvia.